Cutaneous malignancies: Melanoma and nonmelanoma types

Plastic and Reconstructive Surgery

Volumn 127, Issue 3, 2011, Pages

  Netscher, David T ^a,b,c   Leong, Mimi ^a,b,c   Orengo, Ida ^a,b,c   Yang, Deborah ^a,b,c   Berg, Carolyn ^a,b,c   Krishnan, Bhuvaneswari ^a,b,c  

^a Plastic Eye Surgery Associates   (United States)

^b Department of Dermatology ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASAL CELL CARCINOMA; BIOPSY; DIFFERENTIAL DIAGNOSIS; HUMAN; INCIDENCE; MELANOMA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW; SKIN; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; UNITED STATES;

BIOPSY; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; MELANOMA; SKIN; SKIN NEOPLASMS; UNITED STATES;

EID: 79952761115     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318206352b     Document Type: Article

References (160)

1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, Ga.: American Cancer Society; 2008.
2. Robinson JK. Sun exposure, sun protection, and vitamin D. JAMA. 2005;294:1541-1543. (Pubitemid 41362692)
3. Bickers D, Lim HW, Margolis D, et al. The burden of skin diseases. J Am Acad Dermatol. 2006;55:490-500.
4. Austoker J. Cancer prevention in primary care: Melanoma-Prevention and early diagnosis. Br Med J. 1994;308:1682-1686.
5. Overview: Skin cancer-Melanoma, how many people get melanoma skin cancer? Atlanta, Ga.: American Cancer Society, 2007. Available at: http://www.cancer. org/docroot/CRI/content/CRI-2-2-1X.
6. Grimwood RE, Ferris CF, Mercill DB, Huff JC. Proliferating cells of human basal cell carcinoma are located on the periphery of tumor nodules. J Invest Dermatol. 1986;86:191-194. (Pubitemid 16132525)
7. Schanoff LB, Spira M, Hardy SB. Basal cell carcinoma: A statistical approach to rational management. Plast Reconstr Surg. 1967;39:619-624.
8. Rodriguez-Sains RS, Jakobeic FA. Eyelid and conjunctival neoplasms. In: Smith BC, Della Rocca RC, Nesi FA, Lisman RD, eds. Ophthalmic Plastic and Reconstructive Surgery. St. Louis, Mo.: Mosby; 1987:759-770.
9. Netscher DT, Anous M, Spira M. Premalignant skin tumors, basal cell carcinoma, and squamous cell carcinoma. In: Cohen M, ed. Mastery of Plastic and Reconstructive Surgery. Boston: Little, Brown; 1994:309-332.
10. Goodwin WJ, Jesse RH. Malignant neoplasms of the external auditory canal and temporal bone. Arch Otolaryngol. 1980;106:675-679. (Pubitemid 10029304)
11. Byrd KM, Wilson DC, Hoyler SS, Peck GL. Advanced presentation of melanoma in African Americans. J Am Acad Dermatol. 2004;50:21-24. (Pubitemid 38095647)
12. Armstrong BK, Kricker A. Skin cancer. Dermatoepidemiology 1995;13:583-590.
13. OFN Cancer Statistics Registrations. Registrations of Cancers Diagnosed in 2002. London, England: MBI; 2005:33.
14. Emmet AJJ, Austin W, Page G. The Bare Fact: The Effect of the Sun on Skin. Baltimore, Md.: Williams & Wilkins; 1988.
15. Han J, Colditz GA, Hunter DJ. List factors for skin cancers: A nested case-control study within the Nurses' Health Study. Int J Epidemiol. 2006;35:1514-1521. (Pubitemid 46178928)
16. Zametti R, Rosso S, Martinez C, et al. The multicenter South European study "Helios": I. Skin characteristics and sunburnsinbasal cell and squamous carcinomas of the skin. Br J Cancer 1996;73:1440-1446. (Pubitemid 26175683)
17. Westerhof W. The discovery of the human melanocyte. Pigment Cell Res. 2006;19:183-193. (Pubitemid 43742838)
18. Desai A, Krathen R, Orengo I, Medrano EE. The age of skin cancers. Sci Aging Knowl Environ. 2006;2006: pe13.
19. Karagas MR, Stekel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer: Skin Cancer Prevention Group. JAMA. 1992;367:3305-3310.
20. Rigel DS. Epidemiology and prognostic factorsinmalignant melanoma. Ann Plast Surg. 1992;28:7-8.
21. Marghoob AA, Slade J, Falopek TG, et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma: Screening implications. Cancer 1995;75(Suppl 2):707-714.
22. Ferrone C, et al. Clinicopathological features of hand wrist factors for multiple primary melanomas. JAMA. 2005;294:1647-1654. (Pubitemid 41407357)
23. Armstrong BK, Cricker A. How much melanoma is caused by sun exposure? Melanoma Res. 1993;3:395-401. (Pubitemid 24051362)
24. Lacour JP. Carcinogenesis of basal cell carcinomas: Genetics and molecular mechanisms. Br J Dermatol. 2002;146(Suppl. 61):17-19. (Pubitemid 34437805)
25. LeVee GL, Oberhelman L, Anderson T, et al. UVA II exposure to human skin results in decreased immunization capacity, increased induction of tolerance and a unique pattern of epidermal antigen-preventing cell alteration. Photochem Photobiol. 1997;65:622-629. (Pubitemid 27210645)
26. DeLeo V, Dawes L, Jackson R. Density of Langerhans cells in normal vs chronic actinically damaged skin (CADS) of human. Hum Clin Res. 1982;29:592-595.
27. Kripke ML. Immunology and photocarcinogenesis: New light on an old problem. J Am Acad Dermatol. 1986;14:149-155. (Pubitemid 16137946)
28. Bataille V, Vykov VJ, Sasieni P, et al. Photoadaptation to ultraviolet (UV) radiation in vivo: Photo products in epidermal cells following UVB therapy for psoriasis. Br J Dermatol. 2000;143:477-483.
29. Lindelos B, Sigurgeirsson B, Tegner B, et al. PUVA and cancer: A large-scale edpidemeological study. Lancet 1991;338:91-93.
30. Tsai KY, Tsao H. The geneticsof skin cancer. AmJMed Genet. 2004;131 c: 82-92.
31. Akgul B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol. 2006;208:165-175. (Pubitemid 43126110)
32. de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13:768-785. (Pubitemid 29169836)
33. Taylor SF, Cook AE, Leatherbarrow B. Review of patients with basal cell nevus syndrome. Ophthal Plast Reconstr Surg. 2006;22:259-265. (Pubitemid 44510124)
34. Gorlin RJ, Bickers RA, Kellen E, Williamson JJ. The multiple basal-cell nevi syndrome: An analysis of a syndrome consistent of multiple nevoid basal-cell carcinoma, jaw cysts, skeletal anomalies, medulloblastoma, and hyporesponsiveness to parathormone. Cancer 1965;18:89-104.
35. Perry PK, Silverberg NB. Cutaneous malignancy in albinism. Cutis 2001;67:427-430. (Pubitemid 33756290)
36. Czajkowski R, Placek W, Drewa G, Czajkowska A, Uchańska G. FAMMM syndrome: Pathogenesis and management. Dermatol Surg. 2004;30:291-296. (Pubitemid 38313987)
37. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhabition of cyclin D/CDK4. Nature 1993;366:704-707. (Pubitemid 24036021)
38. Bauer J, Garve C. Acquired melanocytic nevi as risk factor for melanoma development: A comprehensive review of epidemiological data. Pigment Cell Res. 2003;16:297-306. (Pubitemid 36597071)
39. Grob J, Gouvernet J, Aymar D, et al. Count of melanocytic nevi as a major indicator of risk for non-familial nodular and superficial spreading melanoma. Cancer 1990;66:387-395. (Pubitemid 20205926)
40. Jones BW, Heyl T. Nevus sebaceous: A report of 140 cases with special regard to the development of secondary malignant tumors. Br J Dermatol. 1970;82:99-117.
41. Chernosky ME. Porokeratosis. Arch Dermatol. 1986;122:869-870. (Pubitemid 16039429)
42. LaVoo JW. Bowenoid papulosis. Dis Colon Rectum 1987;30:62-64. (Pubitemid 17225151)
43. Edwards MT, Hirsch RM, Broadwater JR, Netscher DT, Ames FC. Squamous cell carcinoma arising in previously burned or irradiated skin. Arch Surg. 1989;124:115-117. (Pubitemid 19025915)
44. Marx J. Cancer research: Inflammation and cancer-The link grows stronger. Science 2004;306:966-968. (Pubitemid 39482883)
45. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regiments. J Am Acad Dermatol. 1999;40:177-186. (Pubitemid 29072794)
46. Carucci J. Skin cancer in transplant patients. In: Nouri K, ed. Skin Cancer. New York: McGraw-Hill Medical; 2008:386-387.
47. Bernstein S, Lim K, Brodland D, Heidelberg K. The many faces of squamous cell carcinoma. Dermatol Surg. 1996;22:243-254. (Pubitemid 26088389)
48. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;238:1148-1152.
49. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germ line p16 mutation in familial melanoma. Nat Genet. 1994;8:15-21. (Pubitemid 24274055)
50. Piepkorn M. Melanoma genetics: An update with focus on the CDKN2A (p16)/ARF tumor suppressors. J Am Acad Dermatol. 2000;42:705-722. (Pubitemid 30252871)
51. Sharpless E, Chim L. INK4 a/ARF locus and melanoma. Oncogene 2003;22:3092-3098.
52. Ranade K, Hussussian CJ, Sikorski RS, et al. Mutations associated with familial melanoma impair p16 INK4 function. Nat Genet. 1995;10:114-116.
53. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res. 1994;54:6041-6044. (Pubitemid 24378624)
54. Walker TJ, Hussussian CJ, Flores JF, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet. 1995;4:1845-1852.
55. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12:97-99. (Pubitemid 26013159)
56. Pollock PM, Trent JM. The genetics of cutaneous melanoma. Clin Lab Med. 2000;20:667-690. (Pubitemid 32146703)
57. Castellano M, Pollack PM, Walters MK, et al. CDKN2A/p16 is inactivated in most melanoma lines. Cancer Res. 1997;57:4868-4875. (Pubitemid 27468996)
58. Guldberg P, Kirkin AF, Gronbauk K, et al. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: A novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer. 1997;72:780-783. (Pubitemid 27431520)
59. Sena L, Sakharzadeh S. The genetic basis of common forms of skin cancer. In: Neuri K, ed. Skin Cancer. New York: McGraw-Hill Medical; 2008:51.
60. Erb P, Ji J, Kump E, et al. Apoptosis and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:283-295.
61. Benjamin CL, Melnikova VO, Ananthaswany HN. p53 protein and pathogenesis of melanoma and non-melanoma skin cancer. Adv Exp Med Biol. 2008;624:265-282.
62. Athar M, Tang X, Le JL, Kopelobich L, et al. Hedgehog signaling in skin development and cancer. Exp Dermatol. 2006;15:667-677. (Pubitemid 44145237)
63. High A, Zedan W. Basal cell nevus syndrome. Curr Opin Oncol. 2005;17:160-166. (Pubitemid 40516285)
64. Ludi O. Correlations between sonic hedgehog pathway and basal cell carcinoma. Int J Dermatol. 2007;46:1113-1117.
65. Miller SJ. The National Comprehensive Cancer Network guidelines of care for non-melanoma skin cancers. Dermatol Surg. 2000;26:289-292. (Pubitemid 30146601)
66. Salopek T, et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology: Survey of biopsy practices of pigmented lesions suspected as melanoma. J Am Acad Dermatol. 1995;33:441-.
67. Riker AI, Glass F, Perez I, Cruse CW, Messina J, Sondak VK. Cutaneous melanoma: Methods of biopsy and definitive surgical excision. Dermatol Ther. 2005;18:387-393. (Pubitemid 43096611)
68. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Fort Washington, Pa.: National Comprehensive Cancer Network, 2007. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
69. Russell ED, Carrington PR, Smoller BR. Basal cell carcinoma: A comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol. 1999;41:69-71. (Pubitemid 29336856)
70. Russell ED, Dinehart SM, Smoller BR. Basal cell carcinoma: Shave biopsy versus punch biopsy technique in subtype diagnosis (reply). J Am Acad Dermatol. 2002;46:643.
71. Jones MF, Maloney ME, Billingsley EM. The heterogeneous nature of in vivo basal carcinoma. Dermatol Surg. 1998;24:881-884. (Pubitemid 28405022)
72. Grimwood RE, Ferris CF, Mercill DB, Huff JC. Proliferating cells of human basal cell carcinoma are located on the periphery of tumor nodules. J Invest Dermatol. 1986;86:191-194. (Pubitemid 16132525)
73. Bailin PL, Levine HL, Wood BG, et al. Cutaneous carcinoma of the auricular and periauricular region. Arch Otolaryngol. 1980;106:692-696. (Pubitemid 10029308)
74. Emmett AJJ. Basal cell carcinoma. In: Emmett AJJ, O'Rourke MGE, eds. Malignant Skin Tumors. 2nd ed. Edinburgh: Churchill Livingstone; 1991:109-127.
75. Mohs FE. Modes of spread of cancer. In: Chemosurgery: Microscopically Controlled Surgery for Skin Cancer. Springfield, Ill.: Charles C. Thomas, 1978:256.
76. Barsky SH, Grossman DA, Bhutas S. Desmoplastic basal cell carcinomas possess unique basement membrane-degrading properties. J Invest Dermatol. 1987;88:324-329. (Pubitemid 17035349)
77. Jacobs GH, Rippey JJ, Altin LM. Prediction of aggressive behavior in basal cell carcinoma. Cancer 1982;49:533-537. (Pubitemid 12213452)
78. Lang PG, Maize JC. Histologic evolution of recurrent basal cell carcinoma and treatment implications. J Am Acad Dermatol. 1986;14:186-196.
79. Sloane JP. The value of typing basal cell carcinomas in predicting recurrence after surgical excision. Br J Dermatol. 1977;96:127-132. (Pubitemid 8065490)
80. Scribener Y, Grosshans ED, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtypes. Br J Dermatol. 2002;147:41-47. (Pubitemid 34779436)
81. Salache SJ, Anmonett RA. Morpheaform basal cell epitheliomas: A study of subclinical extensions in a series of 51 cases. J Dermatol Surg Oncol. 1981;7:387-394.
82. Seigle RJ, MacMillan J, Pollack SV. Infiltrative basal cell carcinoma: A non-sclerosing type. J Dermatol Surg Oncol. 1986;12:830-836. (Pubitemid 16045729)
83. Hendrix JD, Parlett HL. Micronodular basal cell carcinoma: A deceptive histologic subtype with frequent clinically undetected tumor extension. Arch Dermatol. 1996;132:295-298.
84. Franseen CC, Taylor GW. Arsenical keratoses and carcinomas. Am J Cancer 1934;22:287-307.
85. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27:241-248.
86. Goldman GD. Squamous cell cancer: A practical approach. Semin Cutan Med Surg. 1998;17:80-95. (Pubitemid 28303408)
87. Mikhail GR. Subungual epidermoid carcinoma. J Am Acad Dermatol. 1984;11:291-298. (Pubitemid 14096803)
88. Mortley R, Kersey P, Lawrence C. Multi-professional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol. 2002;146:18-25. (Pubitemid 34158404)
89. Goepfert H, Dichtel WJ, Medina JE. Perineural invasion in squamous cell carcinoma of the head and neck. Am J Surg. 1984;148:542-547.
90. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol. 1992;26:467-484.
91. Ackerman AB. Editorial: Respect at last for solar keratosis. Dermatopathol Pract Concept. 1997;3:101-103.
92. Dubreuilh WA. Des hyperkeratoses circonscrites. Ann Dermatol Venereol. 1896;27:1158-1160.
93. Halpern AC, Hanson LJ. Awareness of, knowledge of, and attitudes to non-melanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol. 2004;43:638-642. (Pubitemid 39276288)
94. Kao GS. Carcinoma arising in Bowen's disease. Arch Dermatol. 1986;122:1124-1126.
95. Mikhail GR. Cancers, precancers and pseudocancers onthe male genitalia. J Dermatol Surg Oncol. 1980;6:1027-1035.
96. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: A comprehensive clinicopathologic classification-Part II. J Cutan Pathol. 2006;33:261-279.
97. Schwartz RA. Keratoacanthoma. J Am Acad Dermatol. 1994;30:1-19. (Pubitemid 24033812)
98. Netscher DT, Spira M. Basal cell carcinoma: An overview of tumor biology and treatment. Plast Reconstr Surg. 2004;113:74e-94e.
99. Lever WF. Adenoacanthoma of sweat glands. Arch Dermatol Syph. 1947;56:157-171.
100. Goldman GD. Squamous cell carcinoma: A practical approach. Semin Cutan Med Surg. 1998;17:80-95. (Pubitemid 28303408)
101. Salschi SJ. Status of curettage and desiccation in the treatment of primary basal cell carcinoma. J Am Acad Dermatol. 1984;10:285-287.
102. Zacarian SA. Cryosurgery for cancer of the skin. In: Zacarian SA, ed. Cryosurgery for Skin Cancer and Cutaneous Disorders. St. Louis, Mo.: Mosby; 1985:96.
103. Menn H, Robins P, Kopf AW, et al. The recurrent basal cell epithelioma: A study of 100 cases of recurrent retreated basal cell epitheliomas. Arch Dermatol. 1971;103:628-631.
104. Kuijpers DDI, Thissen MR, Berretty PJ, et al. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg. 2007;33:579-587. (Pubitemid 46650368)
105. Kuflik DG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg. 2004;30:297-300.
106. Thissen MR, Nieman FH, Idler AH, et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg. 2000;26:759-764. (Pubitemid 30620522)
107. Spiller WF, Spiller RF. Treatment of basal cell epithelioma by curettage and electrodesiccation. J Am Acad Dermatol. 1984;11:808-814. (Pubitemid 15201322)
108. Werlinger KD, Upton G, Moore AY. Recurrence rates of primary non-melanoma skin cancers treated by surgical excision compared to electrodesiccation- curettage in private dermatological practice. Dermatol Surg. 2002;28:1138-1142. (Pubitemid 36076392)
109. Motley R, Kersey P, Lawrence G. Multiprofessional guidelines for the management of the patient with cutaneous squamous carcinoma. Br J Dermatol. 2002;146:18-25. (Pubitemid 34158404)
110. Rodriguez-Vigil T, Vasquez-Lopez F, Perez-Olivia N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol. 2007;56:91-95. (Pubitemid 44969296)
111. Marks R, Gebauer K, Shumack S, et al. Imiquimod5percent cream in the treatment of superficial basal cell carcinoma: Results of a multicenter six-week dose-response trial. J Am Acad Dermatol. 2001;44:807-813. (Pubitemid 32391169)
112. Huber A, Huber JD, Skinner RB Jr, et al. Topical imiquimod treatment for nodular basal cell carcinomas: An open-label series. Dermatol Surg. 2004;30:429-430. (Pubitemid 38524166)
113. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5 percent imiquimod cream for the treatment of nodular basal cell carcinoma: Comparison of dosing regimens. Arch Dermatol. 2002;138:1165-1171. (Pubitemid 35025688)
114. Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5 percent imiquimod cream: Retrospective study. Dermatol Surg. 2007;33:427-431. (Pubitemid 46570114)
115. Martin-Garcia RS. Imiquimod: An effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg. 2005;31:371-374.
116. Ahmed I, Berth-Jones J. Imiquimod: Novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843845.
117. Gupta AK, Davey V, McPhail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2006;9:209-214. (Pubitemid 44265792)
118. Dubin N, Kopf AW. Multivariant risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol. 1983;119:373-377. (Pubitemid 13135286)
119. Knox JM, Freeman RG, Duncan WC, Heaton CL. Treatment of skin cancer. South Med J. 1967;60:241-246.
120. Epstein E. How accurate is the visual assessment of basal carcinoma margins? Br J Dermatol. 1973;89:37-43.
121. Bart RS, Schrager D, Cops AW, et al. Scalpel excision basal cell carcinomas. Arch Dermatol. 1978;114:739-742. (Pubitemid 8331233)
122. Rapini RP. Comparison of methods for checking surgical margins. J Am Acad Dermatol. 1990;23:288-294. (Pubitemid 20259925)
123. Rowe DE. Comparison oftreatment modalities for basal cell carcinoma. Clin Dermatol. 1995;13:617-620. (Pubitemid 26101094)
124. Rapini RP. Comparison of methods predicting surgical margins. J Am Acad Dermatol. 1990;23:288-294. (Pubitemid 20259925)
125. Rowe D, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol. 1992;26:976-990.
126. Zagrodnik B, Kempf W, Seifert B, et al. Superficial radiotherapy for patients with basal cell carcinoma: Recurrence rates, histologic subtypes, and expression of p53 and bcl-2. Cancer 2003;98:2708-2714. (Pubitemid 37509537)
127. Goldman GD. Squamous cell cancer: A practical approach. Semin Cutan Med Surg. 1998;17:80-95. (Pubitemid 28303408)
128. Veness MJ. Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma. Aust Radiol. 2005;49:365-376. (Pubitemid 43942590)
129. Reschly MJ, Messina J, Zaulyanob LL, et al. Utility of sentinel lymphadenectomy in the management of patients with high-risk cutaneous squamous carcinoma. Dermatol Surg. 2003;29:135-140. (Pubitemid 36188419)
130. Topping A. Five years of sentinel node biopsy for melanoma: The St. George's Melanoma Unit experience. Br J Plast Surg. 2001;57:97-104.
131. Schuchter L, Schultz DJ, Synnestvede M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med. 1996;125:369-375. (Pubitemid 126449706)
132. Clemente CG, Mihm MG, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical phase of primary cutaneous melanoma. Cancer 1996;77:1303-1310. (Pubitemid 26102328)
133. Aitchison TC, Sirel JM, Watt DC, MacKie RM. Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma: Scottish Melanoma Group. Br Med J. 1995;311:1536-1539. (Pubitemid 3006428)
134. Miller JG, MacNeil S. Gender and cutaneous melanoma. Br J Dermatol. 1997;136:657-665. (Pubitemid 27278070)
135. Ronan FG, Han MC, Das Gupta TK. Histologic prognostic indicators in cutaneous malignant melanoma. Semin Oncol. 1998;15:558-565.
136. Massi D, Borgognoni L, Franchi A, et al. Thick cutaneous malignant melanoma: Appraisal of prognostic factors. Melanoma Res. 2000;10:153-164. (Pubitemid 30256878)
137. Sondergaard K, Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases: A multivariate regression analysis. Virchows Arch Anat Pathol Histopathol. 1985;406:179-195. (Pubitemid 15072669)
138. Balch CM, Buzaid AC, Soonj SJ, et al. Final version of the American Joint Committee on Cancer staging system of cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648. (Pubitemid 32786276)
139. Garve C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: State of the art 2006. Melanoma Res. 2007;17:117-127. (Pubitemid 46673905)
140. Garve C. Cutaneous melanoma: Baseline and ongoing laboratory evaluation. Dermatol Ther. 2005;18:413-421.
141. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104:570-579. (Pubitemid 41022815)
142. Lederman JS, Sober AJ. Wide excision as the initial diagnostic procedure in the management of cutaneous melanoma. J Derm Surg Oncol. 1986;12:697-699. (Pubitemid 16099741)
143. Sober AJ, Balch CM. Method of biopsy and incidence of positive margins in primary melanoma. Ann Surg Oncol. 2007;14:274-275. (Pubitemid 46175266)
144. Veronesi U, et al. Thin stage I primary cutaneous malignant melanoma: Comparison of excision with margins of 1 or 3 cm. N Eng J Med. 1991;318:1159-1162.
145. Thomas J, et al. Excision margins in high-risk malignant melanoma. N Eng J Med. 2004;350:757-766. (Pubitemid 38209645)
146. Balch C, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101-108. (Pubitemid 32199405)
147. Cohn-Cedermark G, Rutqvist LE, Andersson R et al. Longterm results of a randomized study by the Swedish Melanoma Study Group on 2 cm versus 5 cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000;89:1495-1501.
148. Jacobs IA, Chang CK, Das Gupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanomas. Ann Surg Oncol. 2003;10:558-561. (Pubitemid 40486920)
149. Wong SL, Brady MS, Busam KJ, Coit DG Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13:302-309. (Pubitemid 43255912)
150. Herschko DD, Robb BW, Lowy AM, et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol. 2006;93:279-285.
151. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:927-932.
152. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: Accuracy and mobidity in MSLT-1, an international multicenter trial. Ann Surg. 2005;242:302-311.
153. Cochran AJ, Morton DL. Detection of clinically relevant melanoma metastases requires focused, not exhaustive, evaluation of sentinel lymph nodes. Am J Surg Pathol. 2006;30:419-420. (Pubitemid 43740180)
154. Pawlik TM, Ross MI, Gershenwald JE. Lymphatic mapping in the molecular era. Ann Surg Oncol. 2004;11:362-374. (Pubitemid 40486745)
155. Starritt EC, Uren RF, Scolyer RA, et al. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12:18-23. (Pubitemid 40486636)
156. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. Surg Clin Oncol. 1998;16:2253-2260. (Pubitemid 28265065)
157. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10:676-680. (Pubitemid 40486900)
158. Thai K. Male apparatus melanoma. Australas J Dermatol. 2001;42:71-81.
159. Tarhini AA, Agarwal SS. Cutaneous melanoma: Available therapy for metastatic disease. Dermatol Ther. 2006;19:19-25.
160. Giblin AD, Thomas J. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2007;60:32-40. (Pubitemid 44763123)